UCLA

UCLA Previously Published Works

Title

In vivo time-resolved autofluorescence measurements to test for glycation of human skin.

Permalink

<https://escholarship.org/uc/item/8453w2xq>

Journal

Journal of biomedical optics, 13(1)

ISSN

1083-3668

Authors

Blackwell, Jennifer
Katika, Kamal M
Pilon, Laurent
et al.

Publication Date

2008

Peer reviewed

In-Vivo Time-Resolved Autofluorescence Measurements to Test for Glycation of Human Skin

Jennifer Blackwell^a, Kamal M. Katika^a, Laurent Pilon^{a *}, Katrina M. Dipple^b,
Seymour R. Levin^c, and Aksone Nouvong^c

^a Mechanical and Aerospace Engineering Department,
Henry Samueli School of Engineering and Applied Science,
University of California, Los Angeles, Los Angeles, CA 90095

^b Departments of Human Genetics and Pediatrics,
David Geffen School of Medicine,
University of California, Los Angeles, CA 90095

^c Department of Veterans Affairs
Greater Los Angeles Healthcare System, Los Angeles, CA 90073
and Departments of Medicine and Surgery
David Geffen School of Medicine, University of California, Los Angeles, CA 90095

*Corresponding Author
UCLA Dept. of Mechanical and Aerospace Engineering
420 Westwood Plaza, 37-132 Engineering IV
Los Angeles, CA 90095-1597
Phone: 310-206-5598
Fax: 310-206-2302
E-mail: pilon@seas.ucla.edu

July 16, 2007

Abstract

This paper presents an evaluation of time-resolved fluorescence measurements on human skin for screening type 2 diabetes. *In-vivo* human skin was excited with a pulse diode at 375 nm and pulse width of 700 ps. Fluorescence decays were recorded at four different emission wavelengths 442, 460, 478 and 496 nm. Experiments were performed on various locations including the palms, arms, legs, and cheeks of a healthy Caucasian subject to test single-subject variability. The fluorescence decays obtained were modeled using a three-exponential decay. The variations in the lifetimes and amplitudes from one location to another were minimal except on the cheek. The study compares the fluorescent decays of 38 diabetic subjects and 37 nondiabetic subjects, with different skin complexions and of ages ranging from 6 to 85 years. The average lifetimes for nondiabetic subjects were 0.5, 2.6 and 9.2 ns with fractional amplitudes of 0.78, 0.18 and 0.03, respectively. The effects of average hemoglobin A1c (HbA1c) from the previous four years and diabetes duration were evaluated. While no significant differences between the fluorescence lifetimes of nondiabetic and diabetic subjects were observed, two of the fractional amplitudes were statistically different. Additionally, none of the six fluorescence parameters correlated with diabetes duration or HbA1c. One of the lifetimes as well as two of the fractional amplitudes differed between diabetic subjects with foot ulcers and nondiabetic subjects.

keywords: skin autofluorescence, time-resolved fluorescence, advanced glycated end-products, diabetes, foot ulcers

1 INTRODUCTION

Fluorescence is the physical phenomenon in which light is emitted by a substance as a result of excited electrons returning to their ground states after absorption of excitation light. Biological tissues contain several endogenous fluorophores such as nicotinamide adenine dinucleotide (NADH), aromatic amino acids such as tryptophan and structural proteins including collagen and elastin [1]. The optical properties of these fluorophores respond to the environment and metabolic status of the tissue, thus making fluorescence spectroscopy a valuable tool to study the state of biological tissues. Fluorescence spectroscopy consists of measuring the fluorescent intensity emitted by fluorophores after being excited by light at a suitable wavelength and can be performed in either a steady-state or time-resolved manner.

Steady-state measurements typically involve measuring either the fluorescence intensity over a range of wavelengths for a fixed excitation wavelength (emission spectra) or the fluorescence intensity at a particular wavelength for a range of excitation wavelengths (excitation spectra). Time-resolved measurements consist of measuring the lifetime of the fluorophores and are much more complex than steady-state spectral measurements due, in part, to the instrumentation required. Steady-state measurements are relatively easy to perform. However, they present some limitations. First, they are intensity dependent and therefore sensitive to excitation light intensity, optical losses in the experimental setup, and absorption and scattering by tissue [2]. Second, the fluorescence intensity is integrated over time and, therefore, information associated with the dynamics of the fluorescence process is lost. Time-resolved measurements, on the other hand, capture the transient decay which depends on the relative concentrations and lifetimes of the fluorophores contributing to the fluorescence signal [2]. They are also extremely sensitive to the local biochemical environment such as the pH and oxygenation which may differ in healthy and diseased tissue [2]. In addition, the fluorophore lifetimes are independent of absolute intensity and so do not change with variations in excitation intensity or optical losses from hemoglobin absorption [2]. Finally, fluorescence lifetime measurements enable the discrimination of fluorophores with overlapping emission spectra but different lifetimes [3]. For example, various tryptophan residues in proteins have similar emission spectra but different lifetimes and thus can be distinguished by time-resolved fluorescence measurements [4].

Time-resolved fluorescence techniques can be performed either in frequency-domain or in time-domain [4]. Frequency-domain techniques involve exciting the sample with a sinusoidally modulated source, which could be a continuous wave laser or a flash lamp, and measuring the phase shift of the emitted light at multiple excitation frequencies to compute the fluorescence lifetime(s) [4]. Alternatively, time-domain measurements typically use ultra-short pulsed light to excite the sample and measure the emitted fluorescence as a function of time, thus enabling one to compute the lifetime of the fluorophore. Note that the pulse width must be of the same order of magnitude or shorter than the fluorescence lifetime. Time-domain measurements are preferred in a clinical setting, because they can be obtained in short acquisition times compared to frequency-domain measurements [3] and they are not affected by ambient light at the collection site [3].

The detection of the diabetic state has become an important issue in recent years as the number of people with diabetes is rising and approximately one-third of people affected by type 2 diabetes in the United States are undiagnosed [5]. The current methods of diagnosis consist of detecting glucose levels in the blood or plasma [6]. Even with screening, the sensitivity is much less than ideal [7]. Once diabetes has been diagnosed, glucose levels and hemoglobin A1c (HbA1c) are currently utilized to follow the efficacy of treatment. The latter is a measure of percent glycated hemoglobin and reflects average glycemic control over the antecedent 3 to 4 months [8]. As a test of short-term glycation, HbA1c does not adequately reflect the accumulation of glycated tissue over a period of years, which may result in diabetic complications. In order to directly measure tissue glycation, a punch biopsy must be taken [9], making it difficult to determine a patient's risk for complications. Thus, a simple, rapid method of screening is being pursued to enable early diagnosis of the disease and follow the efficacy of therapy and the effects of long-term hyperglycemia on tissue.

Spectroscopy-based methods are attractive for diabetes screening and monitoring because they can non-invasively detect some markers of disease progression. For example, the accumulation of advanced glycation products (AGEs) in tissue can potentially be observed via spectroscopy. AGEs are the final products of the complex chemical reaction, known as the Maillard reaction, between sugars, such as glucose, and proteins, lipids and nucleic

acids [9]. While the accumulation of these in tissues is a natural process and serves as a marker of aging [10], elevated blood glucose levels in diabetic individuals results in a more rapid accumulation of AGEs. Some AGEs, such as pentosidine, are known to fluoresce and their fluorescence spectra are well-characterized [11]. It has also been established that the steady-state autofluorescence of skin is correlated with age [10]. Additionally, the formation of these AGEs produce structural changes in tissue proteins, such as collagen [12], which may be detected through spectroscopy measurements [13].

This study evaluated the use of a time-resolved fluorescence device using Time-Correlated Single Photon Counting (TCSPC) on *in-vivo* human skin to screen for type 2 diabetes. An additional goal of this study was to evaluate the use of the time-resolved fluorescence device to assess a patient’s risk for complications based on changes in skin fluorescence caused by AGE formation. Preliminary experiments were performed on the palms, arms, feet, and cheeks of a 31-year-old Caucasian subject to observe measurement variability due to testing location. The device was tested on 37 healthy and 38 diabetic subjects of different age, gender, and skin complexion after obtaining informed consent and approval from UCLA and VA institutional review boards. The study refers to “healthy subjects” as those who are not known to be diabetic, and “diabetic subjects” as those who have been diagnosed with diabetes. Variability in recovered time-resolved fluorescence parameters due to age, skin color, and gender was also tested. Also, 18 diabetic subjects with foot ulcers were compared with 18 age-matched healthy subjects to test for differences due to the development of complications. Finally, the possible origin of these fluorescence lifetimes is discussed. This is the first study to report the application of time-resolved fluorescence to the detection of diabetes and/or monitoring for the development of diabetic complications. This work is of particular importance to studies on skin autofluorescence measurements for non-invasive glucose sensing [14] and the design of implantable glucose sensors based on fluorescence [15]. It would also serve as a baseline for using time-resolved autofluorescence of human skin to monitor other diseases and conditions such as skin cancer, wounds, and ulcers.

2 Current State of Knowledge

2.1 Time-Resolved Fluorescence Measurements on Tissue

In-vivo time-resolved fluorescence measurements have come into prominence only recently and a limited number of studies have been reported in the literature, which are summarized in Table 1. For example, Pradhan *et al.* [16] have used fluorescence lifetime measurements to study breast tissue. They made use of laser pulses of 100 fs pulse width at 310 nm and a streak camera to obtain a 2D map of the fluorescence lifetimes. It was shown that time-resolved fluorescence measurements at an emission wavelength around 340 nm can be used to distinguish malignant tumors from non-malignant breast tissues.

Fluorescence lifetime measurements have also been used to study tissue during endoscopy. Glanzmann *et al.* [17] described a time-resolved fluorescence instrument based on pumped laser excitation sources and a streak camera coupled to a spectrograph as a detector. The instrument was used to measure the fluorescence decays of endogenous fluorophores and of δ -aminolevulinic acid (ALA) induced protoporphyrin IX (PPIX) in an excised human bladder with carcinoma. The authors were able to correctly distinguish healthy tissue, which appeared abnormal in steady-state spectroscopy, from cancerous tissue. The instrument was then used to perform in-situ characterization during endoscopy to obtain time-resolved spectra of tissue fluorescence of human bladder, bronchi, and esophagus [18]. Further studies were conducted by the same group [19] to test the viability of fluorescence lifetime as a new contrast parameter between normal and malignant tissue in the bronchi. However, they were unable to obtain a contrast in the fluorescence lifetime or the spectrum between normal and moderately dysplastic tissue in the spectral region between 510 and 650 nm. Mizeret *et al.* [20] also studied the feasibility of performing endoscopic fluorescence lifetime measurements using frequency modulation techniques in real time in a clinical setting. The instrument made use of an excitation source at 514.5 nm and a detection unit consisting of CCD units with image intensifier tubes. Fluorescence lifetime values for healthy bronchial tissue were reported. Pfefer *et al.* [21] also performed *in-vivo* fluorescence lifetime and spectral measurements on patients undergoing routine endoscopic surveillance for Barrett's esopha-

gus. A time-domain instrument consisting of a laser pulsing at 337 nm with a pulse width of 3 ns and an avalanche photodiode coupled to an oscilloscope was used in the experiments. The excitation wavelengths used were 337 nm and 400 nm and the emission was collected around 550 nm. Results showed that low-risk tissue and high grade dysplasia could not be differentiated based on the observed data.

Furthermore, Schweitzer and co-workers [22, 23] performed fluorescence lifetime studies on the human ocular fundus. They made use of time correlated single photon counting (TCSPC) techniques with a pulsed laser of 300 ps pulse width at a wavelength of 457.9 nm and various emission wavelength ranges. They obtained a lifetime of 1.5 ns in the parapapillary region of the eye and a lifetime of 5 ns in the optical disc which they attributed to collagen. They also showed that breathing 100% oxygen affects the fluorescence lifetimes and speculated that the lifetime of fluorophores present in the retinal pigment epithelium depends on the oxygen supply.

Fluorescence lifetime measurements have also been performed on tissue *in-vitro*. For example, Maarek *et al.* [24] used time-domain *in-vitro* fluorescence lifetime measurements and spectroscopy for diagnosis of atherosclerotic lesions. The instrument consisted of an excitation laser at 337 nm and a pulse width of 3 ns, a microchannel plate photomultiplier attached to a monochromator and connected to a digital oscilloscope. Fluorescence lifetimes were measured at emission wavelengths ranging from 370 nm to 510 nm. The authors were able to discriminate between stable and unstable lesions by studying the time-resolved spectra of components present in the arterial wall, namely structural proteins like collagen, lipoproteins, and cholesterol [25].

Moreover, Cubeddu and co-workers [26, 27] used fluorescence lifetime imaging (FLIM) to study tumors in human skin. The instrumentation consisted of a dye laser pulsing at 405 nm at a pulse width of less than 1 ns and a gated imaging system. An exogenous marker was used to induce selective accumulation of PPIX in proliferative tissue. Tumors were identified using lifetime imaging due to the longer fluorescence lifetime of PPIX (18 ns) compared to that of healthy tissue (~ 10 ns). Siegel *et al.* [28] also used FLIM techniques utilizing a pulsed laser at 415 nm and a pulse width less than 100 fs and a gated optical intensifier to image the autofluorescence from various biological tissue *in-vitro* such as animal tissue,

knee joints, and human teeth. Using this instrument they were able to distinguish between tendon, bone, and surrounding tissue which was not otherwise possible with white light and steady-state fluorescence measurements. Similarly, they showed that various regions in an extracted human tooth can be clearly distinguished using FLIM unlike reflectance and steady-state fluorescence measurements.

Other studies have performed time-resolved fluorescence measurements on human skin. Konig and co-workers [29–31] used 3D autofluorescence lifetime imaging and investigated various tissues of patients with psoriasis, nevi, dermatitis, basaloma, and melanoma *in vitro* as well as the skin of healthy subjects *in-vivo*. Their system was able to achieve a sub-cellular spatial resolution and a temporal resolution of 250 ps. The authors analyzed the fluorescence decays from images obtained at various depths of the skin and reported lifetimes of around 1.85 ns at the stratum corneum and a lifetime of about 2.4 ns at a depth of 50 μm within the stratum spinosum. The same group also reported using multiphoton imaging of skin at an excitation wavelength of 740 nm with a 150 ps resolution [32]. A bi-exponential fit was used to recover a fast lifetime of 0.4 ns and a slow lifetime of 2.4 ns at the stratum spinosum in the epidermis. Additionally, Pitts and Mycek [2] described a time-domain instrument with both spectral and temporal resolution to measure fluorescence lifetimes and emission spectrum *in-vivo* and *in-vitro*. The instrument was based on a pumped dye laser with a pulse width of 4 ns as an excitation source and an avalanche photo diode along with a 1 GHz oscilloscope as a detector. Fluorescence lifetime measurements were performed on human skin *in-vivo* at an excitation wavelength of 337 nm and an emission wavelength of 460 nm. The time-resolved data was fit to a double-exponential decay yielding lifetimes of 0.938 ns and 5.3 ns. The longer lifetime was attributed to the emission from collagen. The instrument was also used to measure fluorescence lifetimes of biomolecules present in human cells.

2.2 Optical Noninvasive Screening of Type 2 Diabetes

A few groups have applied spectroscopic studies to the noninvasive screening of type 2 diabetes. For example, Meerwaldt *et al.* [33] observed steady-state autofluorescence measurements of skin on the arm and lower leg of both diabetic and healthy subjects. Diabetic

and healthy subjects were age- and sex-matched. Using polychromatic excitation between 300 and 420 nm and emission spectrum between 420 and 600 nm, they found a positive correlation between skin autofluorescence intensity with age, diabetes duration, and mean HbA1c levels from the previous year. The fluorescence intensity also correlated well with the concentrations of AGEs in tissue biopsies, such as pentosidine and carboxymethyllysine. This demonstrated the capability of steady-state fluorescence measurements to distinguish diabetics from healthy subjects. The study's primary focus was monitoring disease progression and evaluating the patient's risk for diabetic complications. In a later study, the same group showed that autofluorescence also correlated with severity of diabetic neuropathy [34] and vascular damage in type 2 diabetic subjects [35]. However, the effect of skin color was not addressed in these studies as nearly all subjects recruited were Caucasian. In fact, the researchers reported that data from dark-skinned subjects had to be discarded, because of nearly complete absorption of excitation light by the skin [35]. Otherwise, the steady-state measurements would need to be adjusted to account for skin complexion.

Brown *et al.* [36] clinically evaluated the use of a near-infrared spectroscopic device for its ability to correctly identify diabetic and non-diabetic subjects. The NIR wavelength region under observation in the study was from 1250 to 2500 nm. The diffusely reflected radiation was collected and the tissue absorbance was retrieved. Data from both diabetic and healthy subjects was collected and the device was found to have a sensitivity and specificity of 77.7% and 70%, respectively. Thus, this system's sensitivity and specificity are comparable to the fasting plasma glucose (FPG) test. Although a definite chemical or physiological explanation for the difference between diabetic and non-diabetic patients is yet to be elucidated, they speculate that structural changes in skin due to chronic hyperglycemia contribute to the differentiation between diabetic and non-diabetic subjects. However, the same group's previous work [37] suggested that NIR spectroscopy does not detect AGEs directly.

Recently, Maynard *et al.* [38] reported using a spectroscopic device for type 2 diabetes screening utilizing steady-state fluorescence as well as diffuse reflectance measurements. The fiber-optic probe illuminated skin from the forearm of subjects using LED lights centered at 375, 405, 420, 435 and 460 nm. A spectrometer and charge-coupled device array then collected the light reflected and/or emitted from the skin and detected it. The spectra were

corrected for skin pigmentation, hemoglobin content, and light scattering as well as age to obtain an "intrinsic" dermal fluorescence spectra. This data was then used to determine a likelihood that a subject belonged to the abnormal class, or that they were either pre-diabetic or diabetic. This method of screening was compared to the FPG test and A1C testing. Assuming a clinically relevant specificity of 77.4%, their method showed a sensitivity advantage of 28.8% and 17.1% versus FPG and A1C testing, respectively. The group also reported that the sensitivity of their device was not significantly different between subjects of lighter skin and those with of darker skin. Thus, their study demonstrates the promise of steady-state fluorescence for type 2 diabetes screening if factors such as skin color and age can be adjusted for in measurements. Time-resolved fluorescence may hold promise in diabetes detection by distinguishing different fluorophores emitting at the same wavelength and potentially being able to detect AGEs directly.

3 Materials and Methods

3.1 Experimental Apparatus

The present study made use of the TCSPC technique to measure fluorescence lifetimes of skin. A schematic of the experimental setup is shown in Figure 1. Excitation and emission light were channelled by means of liquid light guides attached to a sensing head. Liquid light guides were used instead of commonly used fiber optics as their transmission and coupling efficiency are higher compared with fiber optics. Both light guides had a diameter of 8 mm, and the excitation light guide was held 1.59 cm above the skin. The receiving end of the collection liquid light guide was held abut against the excitation liquid light guide and angled at 45° to the normal. The sensing head also served to shield the sample surface from ambient light. A total surface area of 6.41 cm² was exposed to excitation light.

The excitation source used was a light emitting diode or LED (PLS 370 diode, PicoQuant GmbH) with its center wavelength at 375 nm with a spectral width of around 10 nm. The full width half maximum of the diode pulses at a repetition rate of 2.5 MHz and average

power of $4.8 \mu\text{W}$ per pulse was 664 ps. The LED was driven by a diode driver (PDL-800 B diode driver, PicoQuant GmbH, Berlin, Germany) at a repetition rate of 5 MHz for all measurements, producing an estimated energy fluence rate of $2.07 \cdot 10^{-6} \text{ W/cm}^2$ at the skin surface for a pulse energy of 2.65 pJ and pulse width of 664 ps. A liquid light guide designed for the UV-visible part of the spectrum (77628, from Spectra-Physics, U.S.A) carried light from the LED to the sensing head. Another liquid light guide designed for the visible part of the spectrum (77631, from Spectra-Physics, U.S.A), was used to collect the fluorescence emission and carry it to a monochromator (SpectraPro-150, Acton Research Corporation, U.S.A.). A photomultiplier tube (PMT) assembly (PMA-M 165 from PicoQuant GmbH) was coupled to the monochromator on the other end. The monochromator slits on the entry and exit of the light path were adjusted manually to maintain a bandwidth of 3 nm.

Finally, for data acquisition, the “sync” output signal from the diode driver and the “start” signal from the PMT assembly were fed to the respective channels on the data acquisition board (TimeHarp 200 from PicoQuant GmbH), via standard 50 Ohms coaxial cables. The “sync” output from the diode driver provided the signal to synchronize the timing electronics on the data acquisition board mounted on a personal computer (PC). The time resolution of our device was estimated to be 200 ps.

3.2 Experimental Procedure and Parameters

The measurement procedure and parameters were arrived at by conducting preliminary studies on the palms, arms, cheeks, and feet of a 31-year-old male Caucasian subject. The fluorescence lifetimes were measured at four different emission wavelengths: 442, 460, 478, and 496 nm. The first wavelength was chosen based on studies reporting that collagen fluorescence exhibited a maximum at around 440 nm when excited by light at 370 nm corresponding to collagenase-digestible collagen cross-links, including AGEs on collagen [39]. The remaining wavelengths were arbitrarily chosen to cover the spectral range up to 500 nm.

In order to measure the fluorescence lifetimes, the monochromator was set to the emission wavelength of interest and the monochromator slits were adjusted to match that particular wavelength. The probe was then placed on the skin surface and the LED was turned on.

The PMT shutter was opened once the sensing head was firmly placed on the skin surface and then the histograms were collected using the TimeHarp software. The probe was held in contact with the palm until 1500 to 5000 counts were acquired in the peak channel. This number was arrived at by considering a trade-off between the duration of the experiments and the signal to noise ratio. The duration of a single measurement ranged from 5 minutes to 20 minutes based on the sensing location and emission wavelength. It was observed that the time taken for each measurement was shortest on the palm, possibly due to the low concentration of melanin. Moreover, higher emission wavelengths required longer durations to achieve these counts due to a lower intensity of the fluorescence. Figure 2 shows a typical sample of *in-vivo* time-resolved fluorescence measurement on human skin along with the χ^2 and associated residuals indicating the goodness of the fit. For an acceptable fit, the χ^2 must be around 1.0 and the residuals should be randomly distributed around 0.

The instrument response function (IRF) was measured by placing the probe on a teflon block for the same number of maximum photon counts of at least 1500 as in the *in-vivo* measurements, with the PMT collecting at 403 nm. The reconvolution software FluoFit version 4.0 was used to recover the lifetimes from the measured fluorescence decays. This software utilized the Marquardt-Levenberg algorithm with a weighting factor $W(i)$ defined as,

$$W(i) = 1/\sqrt{D(i)} \quad (1)$$

where $D(i)$ is the number of counts contained in channel i . An attempt was made to describe the decays with a single-exponential, a bi-exponential, and a tri-exponential model. Only the bi-exponential and the tri-exponential models gave a value of χ^2 around 1.0 which indicated a good fit. However, the bi-exponential model was rejected in favor of the more complicated tri-exponential model due to the presence of oscillations in the plot of the residuals compared to more random residuals for the tri-exponential model as illustrated in Figure 2. Thus, the fluorescence decay could be modeled as

$$F(t) = A_1 e^{-t/\tau_1} + A_2 e^{-t/\tau_2} + A_3 e^{-t/\tau_3} \quad (2)$$

where A_i and τ_i are the fractional amplitude and lifetime, respectively, for decay i . Additionally, it should be noted that initial guess lifetimes were entered to enable faster convergence.

A total of 75 subjects participated in this study. The population characteristics for all subjects are shown in Table 3. The palms were chosen as the sensing location for these subjects due to the shorter duration of the experiments as well as ease of access. The first measurement at 442 nm was performed on the left palm and subsequent measurements at higher wavelengths were performed alternately on the right and left palms.

In addition to time-resolved fluorescence measurements, mean HbA1c values from the previous four years were recorded for diabetic subjects by obtaining medical records with Institutional Review Board approved consent (UCLA IRB #04-12-012-02). Subjects were also recruited from the local Veteran’s Administration (VA) hospital with VA hospital IRB approved consent (VA IRB #PCC 2005-030449). All consent forms were signed prior to testing and collection of medical record data. All available data for each subject from the previous year was averaged and two subsets of this data were compared, one with “high” average HbA1c values and the other with “low” average HbA1c values. Data on duration of diabetes was obtained directly from the subject being tested.

4 Results and Discussion

Table 2 presents a statistical summary of lifetimes τ_1 , τ_2 , and τ_3 and the corresponding fractional amplitudes A_1 , A_2 , and A_3 for six measurements on the left palm of the same healthy subject at an emission wavelength of 442 nm. These experiments were performed over a period of 1 month at different times of the day. The coefficient of variation which represents the variation in measurements is less than 5% in all cases except for the parameters τ_1 and A_3 for which it reaches 7% and 15%, respectively. This shows that measurements performed with this device are highly reproducible for a single subject. Additionally, six consecutive measurements, each lasting 10 minutes, were performed on the same hand within an hour. No noticeable changes in lifetimes, fractional amplitudes, or acquisition times were measured, suggesting that photobleaching was not induced during the measurements.

A set of three experiments were also performed on the inner arm of the same subject over the same period of time and at an emission wavelength of 442 nm. Then, the Student’s t-test [40] was used to test differences in the fluorescence lifetimes obtained on the arm and

the palm for this subject. A two-sample t-test assuming unequal variances was performed. In all cases, a level of significance of $p < 0.05$ was used. It was found that there were no significant differences in the fluorescence lifetime τ_1 . However, the t-test seemed to indicate that there was a difference in the fluorescence lifetimes τ_2 and τ_3 obtained on the arm and the palm at an emission wavelength of 442 nm. Finally, a measurement was also taken on the cheeks and the feet of the same subject. Figure 3 shows the fluorescence lifetimes τ_1 , τ_2 , and τ_3 and their corresponding fractional amplitudes A_1 , A_2 , and A_3 obtained as a function of wavelength and sensing location, namely, the palms, the arms, the cheeks, and the feet. The error bars on the plots of the fluorescence lifetimes represent asymptotic standard errors in the fluorescence lifetimes obtained using the Fluofit software package. Figure 3 indicates that the variations in the lifetimes from one location to another are minimal except on the cheek. Moreover, it was found in the course of the measurements that the time taken for each measurement was the least on the palm, possibly due to the low concentration of melanin. Therefore, the palm was chosen as the sensing location for all the other subjects.

Figure 4 shows the raw data of the fluorescence lifetimes and their corresponding amplitudes at an emission wavelength of 442 nm for 37 healthy subjects and 38 diabetic subjects of various ages, genders, and skin complexion obtained at the VA and UCLA. The error bars represent asymptotic standard errors in the fluorescence lifetimes obtained using the Fluofit software package. In order to further analyze the fluorescence lifetime data, various factors varying from one individual to another were considered namely, (i) skin complexion (ii) gender, and (iii) age. The statistical analysis used was the Student's t-test assuming unequal variance. Based on this test, a two-tailed p-value, defined as the probability that the difference between two groups randomly occurred during the experiment, was assumed statistically significant.

4.1 Effect of Skin Complexion and Gender

Figure 5 shows the fluorescence lifetimes τ_1 , τ_2 , and τ_3 as a function skin complexion for healthy subjects at an emission wavelength of 442 nm. It indicates that the fluorescence lifetimes do not significantly vary for different skin complexions. Using the Fisher's exact

test [40], the fluorescence lifetimes and fractional amplitudes of healthy subjects with dark complexion and light complexion were compared. The light complexion group consisted of 10 Caucasian subjects, age 42 ± 12 years, while the dark complexion group was composed of 10 Hispanic, Persian, South Asian, and African-American subjects, age 39 ± 20 years. Based on these test results, no statistically significant difference in average fluorescence lifetimes and fractional amplitudes exists between these two groups ($p > 0.05$ in all cases). Note that measurements took longer for dark skin. However, skin complexion had no effect on the lifetimes and fractional amplitudes.

Moreover, Figure 6 shows the fluorescence lifetimes as a function of gender for subjects in the same age group at the same emission wavelength of 442 nm. Again, there are no noticeable trends in the fluorescence lifetimes with respect to gender. The comparison of the fluorescence lifetimes and fractional amplitudes of 15 healthy female subjects, average age 42 ± 12 years, and 22 healthy male subjects, average age 48 ± 20 years, did not produce statistically significant differences ($p > 0.05$ for all cases). Thus, Figures 5 and 6 as well as the statistical analysis suggest that fluorescence lifetimes and fractional amplitudes do not vary with skin complexion and gender. The same conclusions were made for other emission wavelengths (data not shown).

4.2 Effect of Age

Finally, an attempt was made to model the fluorescence lifetimes of healthy subjects shown in Figure 4 as a function of age using linear regression. The square of the correlation coefficient, R^2 was less than 0.03 for all three lifetimes, thus indicating that variations in fluorescence lifetimes with age cannot be described by a linear model (data not shown). Moreover, the small regression coefficients in all the cases also indicate that the three lifetimes do not depend on the age of the subject. Student's t-tests were performed on all six parameters (fluorescence lifetimes and fractional amplitudes) comparing young and old healthy subjects. In addition, 15 subjects in both the young and old groups were compared with average ages of 31 ± 7 years and 63 ± 11 years, respectively. No statistically significant difference was detected for any of the parameters ($p > 0.05$). Thus, the lifetimes and fractional amplitudes obtained

for healthy subjects are statistically independent of age, gender, and skin complexion. Table 4 presents the mean values and the standard deviations of the fluorescence lifetimes and their corresponding fractional amplitudes for healthy subjects, providing reference values for healthy human skin. This clearly demonstrates the advantage of time-resolved fluorescence over steady-state fluorescence in that it is insensitive to age and skin complexion.

4.3 Effect of Diabetes

Table 4 summarizes the experimental data collected for 18 healthy subjects and 27 age-matched diabetic subjects. Their fluorescence lifetimes and fractional amplitudes were compared by means of an unpaired Student's t-tests. Only the fractional amplitudes A_1 and A_2 produced statistically significant differences in the means of the diabetic and the healthy patients. This was based on the criteria that $p < 0.05$ for the difference between average values to be considered significant. Additionally, the relative contributions of each lifetime to the overall intensity of diabetic and healthy subjects were compared using the Student's t-test. The fractional contribution of a single lifetime to the steady-state intensity can be defined by the following equation [4],

$$I_i = (\tau_i A_i) / \sum_{i=1}^n (\tau_i A_i) \quad (3)$$

However, no statistically significant differences were found for any of the three fluorescence lifetimes considered. The same conclusions were reached for other emission wavelengths considered (data not shown).

Further testing was performed on only the diabetic subjects comparing duration of diabetes as well as average HbA1c values over the past four years. To test the effect of diabetes duration, the diabetic subjects were divided into two groups with an average of 11 ± 5 years since diagnosis in the shorter duration group and 24 ± 7 years in the longer duration group. However, no statistically significant difference was found between these two groups when performing the unpaired Student's t-test. Similarly, any correlation with average HbA1c from the previous four years was tested by dividing the diabetic subjects into two groups: one with a low average HbA1c of 6.9 ± 0.7 % and higher average HbA1C of 9.8 ± 0.9 %.

No significant difference was detected between these two groups ($p > 0.05$ for all cases).

Additionally, 18 diabetic subjects with foot ulcers, aged 62 ± 8 years, were compared with 18 age-matched healthy subjects, average age 57 ± 15 years, using the Student's t-test. Diabetic subjects with foot ulcers were specifically chosen because many diabetic subjects who develop ulcers also have other co-morbidities associated with diabetes [41,42]. Thus, this group represents subjects whose AGE accumulation is expected to be much higher than other diabetic subjects. Not only were statistically significant differences noted between the two groups for fractional amplitudes A_1 and A_2 , but also differences in lifetime τ_1 between the two groups was also statistically significant. The test results are presented in Table 5. Given the long half-life of collagen in skin (~ 15 years) [43], one can expect changes in the time-resolved fluorescence properties of skin to correlate more with the occurrence of diabetic complications than with HbA1c values. This measurement would indicate the long-term accumulation of AGEs and other oxidative damage. The rate at which tissue accumulates AGEs is also dependent on various genetic or metabolic factors [44]. Therefore, not all diabetic subjects are as susceptible to the development of complications, in spite of poor blood glucose control. The development of complications cannot be predicted by conventional treatment monitoring such as blood glucose measurements and HbA1C tests. Finally, 9 diabetic subjects without foot ulcers were compared with 18 age-matched diabetic subjects with foot ulcers using the Student's t-test. No statistically significant differences between the two groups were detected between the three fluorescence lifetimes and their corresponding fractional amplitudes. This indicates that the differences between the amplitudes A_1 and A_2 between 18 healthy and 27 diabetic subjects reported earlier might be mainly due to the diabetic subjects with foot ulcers.

While a previous study by Meerwaldt *et al.* [33] showed that steady-state autofluorescence measurements correlated with age, diabetes duration, mean HbA1c of the previous year, the present study did not find any significant relationships between the fluorescence lifetimes and amplitudes and these variables. Meerwaldt *et al.* [33] used a polychromatic excitation source emitting at wavelengths ranging from 300 to 420 nm and fluorescence was measured from 420 to 600 nm. This is in contrast with the present study where the excitation source was a monochromatic diode emitting at 375 nm (spectral width of around 10 nm) and

fluorescence was measured at 442, 460, 478 and 496 nm (spectral width of around 3 nm). It is speculated that these differences in the excitation wavelength might be the source of the different conclusions obtained in the two studies.

4.4 Identification of Fluorophores

In an earlier study on fluorescence lifetime measurements on human skin [32], two fluorescence lifetimes of 0.4 ns and 2.4 ns at the stratum spinosum were reported using multi-photon excitation at 740 nm, equivalent to single photon excitation at 370 nm. In the present study, similar values were found when the decays were fit to a tri-exponential model. This suggests that the fluorophores with the high fractional amplitudes in our measurements originate, at least in part, from the stratum spinosum. Our measurements are detecting another fluorophore as well, perhaps deeper in the tissue, which would explain the lower contribution of this fluorophore to the overall fluorescence signal. The similarities between our results and the previously reported data help to validate our results in spite of using different multi-exponential models. Moreover, the shorter two lifetimes τ_1 around 0.4 ns and τ_2 around 2.7 ns observed in our measurements were similar to the lifetimes of free and protein-bound NADH reported in literature [30, 45]. Indeed, Schneckenburger [45] studied the autofluorescence from cultivated endothelial cells and determined the fluorescence lifetime of free and protein-bound NADH to be between 0.4 and 0.5 ns and between 2.0 to 2.5 ns, respectively. In addition, Konig and Riemann [30] also reported a fluorescence lifetime of 2.7 ns at a depth of 50 μm within the skin which could possibly be attributed to bound NADH. Based on these studies, it is speculated that the two shorter fluorescence lifetimes τ_1 and τ_2 correspond to free and protein-bound NADH. This suggests that the differences in fractional amplitudes A_1 and A_2 observed between diabetic and healthy subjects are related to the metabolic states of their tissues rather than directly detecting the presence of glycation products. However, as the presence of glycation products is known to increase tissue oxidative stress [46, 47], they may have an indirect effect on our measurements.

Furthermore, it is speculated that the third observed average lifetime τ_3 equal to 9.2 ns for healthy subjects corresponds to collagen cross-links formed by advanced glycation end

products (AGEs) [33, 37]. However, our data on diabetic subjects seems to contradict this speculation. The longest lifetime τ_3 and the corresponding fractional amplitude A_3 are not significantly different between diabetic and healthy subjects. Given the known correlation between AGEs and diabetes and skin steady-state autofluorescence [33], one would expect the fractional amplitude of the third lifetime to increase with increasing AGE accumulation, if the lifetime could be attributed to AGEs. With elevated concentration of AGEs in the skin, their fluorescence signal would be stronger and, thus, contribute a higher fractional intensity. Further *in-vitro* experimentation is needed to precisely determine the origin of these lifetimes.

5 Conclusions

This paper presents the design and implementation of an experimental apparatus based on Time-Correlated Single Photon Counting assembled to measure autofluorescence lifetimes of human skin. With an excitation wavelength of 375 nm and pulse width of 700 ps, fluorescence was detected at wavelengths of 442 nm, 460 nm, 478 nm and 496 nm. Initial experiments provided a statistical analysis of the fluorescence lifetimes obtained on the inner arm, palm, feet, and the cheeks of a 31-year-old healthy male Caucasian subject showed differences between sensing locations for τ_2 and τ_3 while there were no differences in τ_1 . The assembled device was then tested on the palms of 37 healthy subjects and 38 diabetic subjects. Skin autofluorescence lifetimes and associated amplitudes were obtained from these subjects. The effect of several factors such as age, gender, skin complexion, diabetes duration, and average HbA1c over four years were explored. In all cases, the fluorescence decay was fit to a multi-exponential model with three average fluorescence lifetimes of 0.5 ns, 2.6 ns, and 9.2 ns and associated average fractional amplitudes of 0.78, 0.18, and 0.03, respectively, for non-diabetic subjects. However, they were independent of the skin complexion and the gender of the subjects. The lifetimes of diabetic and non-diabetic subjects were compared, with the only statistically significant differences being between fractional amplitudes A_1 and A_2 of the two groups. No differences in any parameters were observed between subjects due to HbA1c values or diabetes duration. However, comparison between diabetic subjects with foot

ulcers and healthy subjects showed statistically significant differences not only in fractional amplitudes A_1 and A_2 , but also in lifetime τ_1 . Finally, there were no statistically significant differences between the lifetimes and corresponding amplitudes of diabetic subjects with and without foot ulcers. Data of healthy subjects is of particular interest especially for using fluorescence lifetimes of NADH to non-invasively sense glucose concentrations [14] as well as monitoring diseases and skin conditions such as skin cancer, wounds, and ulcers.

6 Acknowledgement

The authors would like to thank Dr. Mark Elliot for insightful discussion. This work was supported by UCLA Office of Intellectual Property Administration, UCLA Faculty Senate Grant and by the Diabetes Action Research and Education Foundation.

References

- [1] R. Richards-Kortum and E. Sevick-Muraca, “Quantitative optical spectroscopy for tissue diagnostics,” *Annual Review of Physical Chemistry* **47**, pp. 555–606, 1996.
- [2] J. D. Pitts and M.-A. Mycek, “Design and development of a rapid acquisition laser-based fluorometer with simultaneous spectral and temporal resolution,” *Review of Scientific Instruments* **72**, pp. 3061–3072, 2001.
- [3] Q. Fang, T. Papaioannou, J. A. Jo, R. Vaitha, K. Shastry, and L. Marcu, “Time-domain laser-induced fluorescence spectroscopy apparatus for clinical diagnostics,” *Review of Scientific Instruments* **75**(1), pp. 151–162, 2004.
- [4] J. R. Lakowicz, *Principles of Fluorescence Spectroscopy*, Kluwer Academic/Plenum Publishers, New York, NY, 1999.
- [5] American Diabetes Association, “Economic costs of diabetes in the U.S. in 2002,” *Diabetes Care* **26**, pp. 917–932, 2003.

- [6] American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” *Diabetes Care* **29**, **Supplement 1**, pp. S43–S48, 2006.
- [7] M. Engelgau, K. Narayan, and H. W.H., “Screening for type 2 diabetes,” *Diabetes Care* **23**, pp. 1563–1580, 2000.
- [8] D. B. Sacks, D. E. Bruns, D. E. Goldstein, N. K. Maclaren, J. M. McDonald, and M. Parrott, “Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus,” *Clinical Chemistry* **48**, pp. 436–472, 2002.
- [9] R. Singh, A. Barden, T. Mori, and L. Beilin, “Advanced glycation end-products: a review,” *Diabetologia* **44**, pp. 129–146, 2001.
- [10] R. Na, I. Stender, M. Henrikson, and H. Wulf, “Autofluorescence of human skin is age-related when corrected for skin-pigmentation and redness,” *Journal of Investigative Dermatology* **116**, pp. 536–540, 2001.
- [11] D. Sell, R. Nagaraj, S. Grandhee, P. Odetti, A. Lapolla, J. Fogarty, and V. Monnier, “Pentosidine: a molecular marker for the cumulative damage due to proteins in diabetes, aging and uremia,” *Diabetes/Metabolism Review* **7**(4), pp. 239–251, 1991.
- [12] V. Monnier, G. Mustata, K. Beimel, O. Reihl, M. Lederer, D. Zhenyu, and D. Sell, “Cross-linking of the extracellular matrix by the Maillard reaction in aging and diabetes,” *Annals of the New York Academy of Sciences* **1043**, pp. 533–544, 2005.
- [13] M. Meli, R. Granouillet, E. Reynaud, A. Chamson, J. Frey, and C. Perier, “In vitro glycoxidation of insoluble fibrous type i collagen: solubilization and advanced glycation end products,” *Journal of Protein Chemistry* **22**(6), pp. 527–531, 2003.
- [14] N. Evans, L. Gnudi, O. Rolinski, D. Birch, and J. Pickup, “Glucose-dependent changes in NAD(P)H-related fluorescence lifetime of adipocytes and fibroblasts in vitro: Potential for non-invasive glucose sensing in diabetes mellitus,” *Journal of Photochemistry and Photobiology B: Biology* **80**(2), pp. 122–129, 2005.

- [15] D. P. O’Neal, M. J. McShane, M. V. Pishko, and G. L. Cote, “Implantable biosensors: analysis of fluorescent light propagation through skin,” *Optical Diagnostics and Sensing of Biological Fluids and Glucose and Cholesterol Monitoring* **4263**(1), pp. 20–24, SPIE, 2001.
- [16] A. Pradhan, B. B. Das, K. M. Yoo, R. R. Alfano, J. Cleary, R. Prudente, and E. J. Celmer, “Time-resolved fluorescence of benign and malignant breast tissues,” *Proceedings of the SPIE* **1599**(1), pp. 81–84, 1992.
- [17] T. M. Glanzmann, J.-P. Ballini, P. Jichlinski, H. van den Bergh, and G. A. Wagnieres, “Tissue characterization by time-resolved fluorescence spectroscopy of endogenous and exogenous fluorochromes: apparatus design and preliminary results,” *Proceedings of the SPIE* **2926**, pp. 41–50, 1996.
- [18] T. Glanzmann, J.-P. Ballini, H. van den Bergh, and G. Wagnieres, “Time-resolved spectrofluorometer for clinical tissue characterization during endoscopy,” *Review of Scientific Instruments* **70**, pp. 4067–4077, 1999.
- [19] T. M. Glanzmann, P. Uehlinger, J.-P. Ballini, A. Radu, T. Gabrecht, P. Monnier, H. van den Bergh, and G. A. Wagnieres, “Time-resolved autofluorescence spectroscopy of the bronchial mucosa for the detection of early cancer: clinical results,” *Proceedings of the SPIE* **4432**, pp. 199–209, 2001.
- [20] J. Mizeret, T. Stepinac, M. Hansroul, A. Studzinski, H. van den Bergh, and G. Wagnieres, “Instrumentation for real-time fluorescence lifetime imaging in endoscopy,” *Review of Scientific Instruments* **70**, pp. 4689–4701, 1999.
- [21] T. J. Pfefer, D. Y. Paithankar, J. M. Ponerros, K. T. Schomacker, and N. S. Nishioka, “Temporally and spectrally resolved fluorescence spectroscopy for the detection of high grade dysplasia in Barrett’s esophagus,” *Lasers in Surgery and Medicine* **32**(1), pp. 10–16, 2003.
- [22] D. Schweitzer, A. Kolb, M. Hammer, and E. Thamm, “Tau-mapping of the autofluorescence of the human ocular fundus,” *Proceedings of the SPIE* **4164**, pp. 79–89, 2000.

- [23] D. Schweitzer, A. Kolb, and M. Hammer, “Autofluorescence lifetime measurements in images of the human ocular fundus,” *Proceedings of the SPIE* **4432**, pp. 29–39, 2001.
- [24] J.-M. I. Maarek, L. Marcu, M. C. Fishbein, and W. S. Grundfest, “Time-resolved fluorescence of human aortic wall: Use for improved identification of atherosclerotic lesions,” *Lasers in Surgery and Medicine* **27**, pp. 241–254, 2000.
- [25] L. Marcu, W. S. Grundfest, and J.-M. I. Maarek, “Arterial fluorescent components involved in atherosclerotic plaque instability: differentiation by time-resolved fluorescence spectroscopy,” *Proceedings of the SPIE* **4244**, pp. 428–433, 2001.
- [26] R. Cubeddu, A. Pifferi, P. Taroni, A. Torricelli, G. Valentini, and E. Sorbellini, “Fluorescence lifetime imaging: an application to the detection of skin tumors,” *IEEE Journal of Selected Topics in Quantum Electronics* **5**(4), pp. 122–132, 1999.
- [27] R. Cubeddu, D. Comelli, C. D’Andrea, P. Taroni, and G. Valentini, “Clinical system for skin tumour detection by fluorescence lifetime imaging,” *Engineering in Medicine and Biology* **3**, pp. 2295 – 2296, 2002.
- [28] J. Siegel, D. S. Elson, S. E. D. Webb, K. C. B. Lee, A. Vlandas, G. L. Gambaruto, S. L.-Fort, M. J. Lever, P. J. Tadrous, G. W. H. Stamp, A. L. Wallace, A. Sandison, T. F. Watson, F. Alvarez, and P. M. W. French, “Studying biological tissue with fluorescence lifetime imaging: microscopy, endoscopy, and complex decay profiles,” *Applied Optics* **42**(16), pp. 2995–3004, 2003.
- [29] K. Koenig, U. Wollina, I. Riemann, C. Peukert, K.-J. Halbhuber, H. Konrad, P. Fischer, V. Fuenfstueck, T. W. Fischer, and P. Elsner, “Optical tomography of human skin with subcellular spatial and picosecond time resolution using intense near infrared femtosecond laser pulses,” *Proceedings of the SPIE* **4620**, pp. 191–201, 2002.
- [30] K. Konig and I. Riemann, “High-resolution multiphoton tomography of human skin with subcellular spatial resolution and picosecond time resolution,” *Journal of Biomedical Optics* **8**(3), pp. 432–439, 2003.

- [31] I. Riemann, E. Dimitrov, P. Fischer, A. Reif, M. Kaatz, P. Elsner, and K. Konig, “High-resolution multiphoton tomography of human skin in vivo and in vitro,” *Proceedings of the SPIE* **5463**, pp. 21–28, 2004.
- [32] A. Ehlers, I. Riemann, T. Anhut, M. Kaatz, P. Elsner, and K. Konig, “Fluorescence lifetime imaging of human skin and hair,” *Proceedings of SPIE* **6089**, pp. N1–N10, 2006.
- [33] R. Meerwaldt, R. Graaff, P. H. N. Oomen, T. P. Links, J. J. Jager, N. L. Alderson, S. R. Thorpe, J. W. Baynes, R. O. B. Gans, and A. J. Smit, “Simple non-invasive assessment of advanced glycation endproduct accumulation,” *Diabetologia* **47**, pp. 1324–1330, 2004.
- [34] R. Meerwaldt, T. P. Links, R. Graaff, K. Hoogenberg, J. D. Lefrandt, J. W. Baynes, R. O. B. Gans, and A. J. Smit, “Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy,” *Diabetologia* **48**, pp. 1637–1644, 2005.
- [35] H. L. Lutgers, H. J. Bilo, R. Graaff, R. O. Gans, T. P. Links, A. J. Smit, and L. J. Ubink-Veltmaat, “Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes,” *Diabetes Care* **29**(12), pp. 2654–2659, 2006.
- [36] C. Brown, H. Davis, M. Ediger, C. Fleming, E. Hull, and M. Rohrscheib, “Clinical assessment of near-infrared spectroscopy for noninvasive diabetes screening,” *Diabetes Technology and Therapeutics* **7**(3), pp. 456–466, 2005.
- [37] E. Hull, M. Ediger, A. Unione, E. Deemer, M. Stroman, and J. Baynes, “Noninvasive, optical detection of diabetes: model studies with porcine skin,” *Optics Express* **12**(19), pp. 4496–4510, 2004.
- [38] J. Maynard, M. Rohrscheib, J. Way, C. M. Nguyen, and M. N. Ediger, “Noninvasive type 2 diabetes screening: Superior sensitivity to fasting plasma glucose and a1c,” *Diabetes Care* **30**(5), pp. 1120–1124, 2007.
- [39] R. H. Na, I. M. Stender, M. Henriksen, and H. C. Wulf, “Autofluorescence of human skin is age-related after correction for skin pigmentation and redness,” *Journal of Investigative Dermatology* **116**, pp. 536–540, 2001.

- [40] S. Glantz, *Primer of Biostatistics*, McGraw Hill, New York, NY, 2002.
- [41] R. Nelson, D. Gohdes, J. Everhart, J. Hartner, F. Zwemer, D. Pettitt, and W. Knowler, “Lower-extremity amputations in NIDDM: 12-yr follow-up study in Pima Indians,” *Diabetes Care* **11**(1), pp. 8–16, 1988.
- [42] G. Reiber, R. Pecoraro, and T. Koepsell, “Risk factors for amputation in patients with diabetes mellitus. a case control study,” *Annals of Internal Medicine* **117**(2), pp. 97–105, 1992.
- [43] N. Verzijl, J. DeRoot, S. Thorpe, R. A. Bank, J. N. Shaw, T. J. Lyons, J. W. J. Bijlsma, F. P. J. G. Lafeber, J. W. Baynes, and J. M. TeKoppele, “Effect of collagen turnover on the accumulation of advanced glycation end products,” *Journal of Biological Chemistry* **275**(50), pp. 39027–39031, 2000.
- [44] H. Vlassara and M. Palace, “Diabetes and advanced glycation endproducts,” *Journal of Internal Medicine* **251**(2), pp. 87–101, 2002.
- [45] H. Schneckenburger, M. Wagner, P. Weber, W. S. Strauss, and R. Sailer, “Autofluorescence lifetime imaging of cultivated cells using a UV picosecond laser diode,” *Journal of Fluorescence* **14**(5), pp. 649 – 654, 2004.
- [46] T. Wendt, N. Tanji, J. Guo, B. Hudson, A. Bierhaus, R. Ramasamy, B. Arnold, P. Nawroth, S. F. Yan, V. D’Agati, and A. Schmidt, “Glucose, glycation and RAGE: implication for amplification of cellular dysfunction in diabetic nephropathy,” *Journal of the American Society of Nephrology* **14**(5), pp. 1383–1395, 2003.
- [47] J. W. Baynes and S. R. Thorpe, “Role of oxidative stress in diabetic complications: a new perspective on an old paradigm,” *Diabetes* **48**(1), pp. 1–9, 1999.
- [48] D. Schweitzer, M. Hammer, F. Schweitzer, R. Anders, T. Doebbecke, S. Schenke, E. R. Gaillard, and E. R. Gaillard, “In vivo measurement of time-resolved autofluorescence at the human fundus,” *Journal of Biomedical Optics* **9**(6), pp. 1214–1222, 2004.

Table 1: Experimental studies of time-resolved fluorescence spectroscopy on human tissues.

Ref	Excitation Wavelength	Emission Wavelength	Spectroscopy method	Sensing region	<i>in-vivo</i> / <i>in-vitro</i>
[2]	337.1 nm	N.A	time-domain using an APD and fast oscilloscope	human skin	<i>in-vivo</i>
[16]	310 nm	340 and 440 nm	time-domain using a streak camera	breast tissue	<i>in-vitro</i>
[17]	337.1 nm 425, 476 and 500 nm	500-680nm	time-domain using a streak camera	human bladder	<i>in-vitro</i>
[18]	337.1 nm, 480 nm	375-515 nm, 525-615 nm	time-domain using a streak camera	bladder, bronchii, oesophagus	<i>in-vivo</i>
[19]	406 nm	430-680 nm	time-domain using a streak camera	bronchii	<i>in-vivo</i> , endoscopy
[20]	514.5 nm	550-650 nm	frequency domain	bronchii	<i>in-vivo</i> , endoscopy
[21]	337 nm, 400 nm	550 nm	time-domain using a gated intensified diode array	esophagus	<i>in-vivo</i> , endoscopy
[22, 23, 48]	458 nm, 446 nm	510-700 nm	time-domain using TCSPC	human ocular fundus	<i>in-vivo</i>
[24, 25]	337.1nm	370-510 nm	time-domain using a transient digitizer	aorta, and its components	<i>in-vitro</i>
[26, 27]	405 nm	N.A.	time-domain using time gating	skin tumors	<i>in-vitro</i>
[28]	415 nm	N.A.	time-domain using time gating	rabbit knee joint and human tooth	<i>in-vitro</i>
[29–31]	750-850 nm	N.A.	time-domain using TCSPC	human skin	<i>in-vivo</i>

Table 2: Statistics of fluorescence lifetimes and their corresponding amplitudes obtained from 6 measurements on the left palm of a 31-year-old healthy Caucasian male subject at an excitation and an emission wavelength of 375 nm and 442 nm, respectively.

Parameter	Mean Value	Standard Deviation	Coefficient of Variation
Fluorescence Lifetime τ_1 (ns)	0.409	0.029	7.09%
Amplitude A_1	0.783	0.013	1.66 %
Fluorescence Lifetime τ_2 (ns)	2.591	0.129	4.98%
Amplitude A_2	0.183	0.008	4.37%
Fluorescence Lifetime τ_3 (ns)	8.880	0.410	4.62 %
Amplitude A_3	0.034	0.005	14.71%

Table 3: Population characteristics of healthy and diabetic subjects recruited for this study.

	Male/Female	Age Range (years)	African-American	Asian	Caucasian	Hispanic	Persian	South Asian
Healthy	22/15	10-85	4	6	18	5	2	2
Diabetic	33/5	6-80	10	1	17	10	0	0

Table 4: Statistics of the decay parameters obtained on the left palm of 18 healthy and 27 diabetic subjects at an emission wavelength of 442 nm. The reported P-values were obtained using the unpaired Student's t-test to compare healthy and diabetic populations.

Parameter	Group	Mean Value	Variance	P-Value
Fluorescence Lifetime τ_1 (ns)	Healthy	0.477	0.002	0.07
	Diabetic	0.504	0.003	
Amplitude A_1	Healthy	0.769	0.0008	0.01
	Diabetic	0.749	0.0004	
Fluorescence Lifetime τ_2 (ns)	Healthy	2.74	0.05	0.21
	Diabetic	2.82	0.06	
Amplitude A_2	Healthy	0.196	0.0004	0.002
	Diabetic	0.215	0.0002	
Fluorescence Lifetime τ_3 (ns)	Healthy	9.35	0.85	0.10
	Diabetic	9.79	0.61	
Amplitude A_3	Healthy	0.035	0.0001	0.72
	Diabetic	0.036	0.0001	

Table 5: Statistics of the decay parameters on the left palm of 18 diabetic subjects with foot ulcers and 18 age-matched healthy subjects at an emission wavelength of 442 nm. The reported P-values were obtained using the unpaired Student's t-test to compare healthy and diabetic populations.

Parameter	Group	Mean Value	Variance	P-Value
Fluorescence Lifetime τ_1 (ns)	Healthy	0.477	0.002	0.038
	Diabetic with foot ulcers	0.510	0.002	
Amplitude A_1	Healthy	0.769	0.001	0.012
	Diabetic with foot ulcers	0.761	0.0003	
Fluorescence Lifetime τ_2 (ns)	Healthy	2.73	0.05	0.05
	Diabetic with foot ulcers	2.86	0.03	
Amplitude A_2	Healthy	0.196	0.0003	0.002
	Diabetic with foot ulcers	0.217	0.0004	
Fluorescence Lifetime τ_3 (ns)	Healthy	9.34	0.85	0.07
	Diabetic with foot ulcers	9.81	0.24	
Amplitude A_3	Healthy	0.036	0.0001	0.91
	Diabetic with foot ulcers	0.035	0.0001

Figure 1: Schematic of the experimental set-up including, (1) diode driver, (2) LED, (3) UV liquid light guide, (4) sample probe, (5) visible liquid light guide, (6) monochromator, (7) photomultiplier tube, and (8) personal computer.

Figure 2: A typical measurement of fluorescence decay from human skin (dark gray), IRF (light gray), and exponential decay retrieved from reconvolution (black line) with the Time-Harp Fluofit 4.0 software package.

Figure 3: Effect of sensing location on fluorescence lifetimes τ_1 , τ_2 , and τ_3 and fractional amplitudes A_1 , A_2 , and A_3 as a function of wavelength for a 31-year-old Causcasian male subject.

Figure 4: Effect of age on the fluorescence lifetimes τ_1 , τ_2 , and τ_3 and fractional amplitudes A_1 , A_2 , and A_3 for healthy and diabetic subjects at an emission wavelength of 442 nm.

Figure 5: Effect of skin complexion on the fluorescence lifetimes τ_1 , τ_2 , and τ_3 and fractional amplitudes A_1 , A_2 , and A_3 as a function of age for healthy subjects at an emission wavelength of 442 nm.

Figure 6: Effect of gender on the fluorescence lifetimes τ_1 , τ_2 , and τ_3 and fractional amplitudes A_1 , A_2 , and A_3 as a function of age for healthy subjects at an emission wavelength of 442 nm.